These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1191 related items for PubMed ID: 31429351

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, Garment AR, Giftos J, Lee JD.
    Addict Sci Clin Pract; 2019 Oct 01; 14(1):37. PubMed ID: 31570100
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B, Capone MJ.
    Int J Drug Policy; 2018 Apr 01; 54():9-17. PubMed ID: 29324253
    [Abstract] [Full Text] [Related]

  • 6. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ.
    Subst Abuse Treat Prev Policy; 2020 Sep 14; 15(1):69. PubMed ID: 32928272
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.
    Du CX, Shi J, Tetrault JM, Madden LM, Barry DT.
    Fam Pract; 2022 Mar 24; 39(2):234-240. PubMed ID: 34893825
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
    Camenga DR, Colon-Rivera HA, Muvvala SB.
    J Stud Alcohol Drugs; 2019 Jul 24; 80(4):393-402. PubMed ID: 31495374
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
    Choi SA, Yan CH, Gastala NM, Touchette DR, Stranges PM.
    J Subst Use Addict Treat; 2024 May 24; 160():209237. PubMed ID: 38061629
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY, Presnall N, Mintz CM, Borodovsky JT, Bhat NR, Bierut LJ, Grucza RA.
    JAMA Netw Open; 2021 Feb 01; 4(2):e210061. PubMed ID: 33625511
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM, Byrd DJ, Clarke TJ, Campbell TB, Ohuoha C, McCance-Katz EF.
    Drug Alcohol Depend; 2019 Dec 01; 205():107616. PubMed ID: 31678836
    [Abstract] [Full Text] [Related]

  • 19. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
    Kennedy-Hendricks A, Bandara S, Merritt S, Barry CL, Saloner B.
    Drug Alcohol Depend; 2021 Sep 01; 226():108881. PubMed ID: 34218008
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.